THEUNITEDREPUBLICOFTANZANIA

MINISTRYOFHEALTH

TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY

PUBLIC ASSESSMENT REPORT FOR GABALIN 300 (GABAPENTIN 300 MG) CAPSULE

Version number 1.0
10 October 2023

TMDA Headquarters, Plot No. 56/1, Block E, Kisasa B Centre, Hombolo Road, P. O. Box 1253, Dodoma - Tanzania,
Tel: +255 (26) 2961989/2061990/ +255(22) 2450512/2450751/2452108,
Email: info@tmda.go.tz, Website: www.tmda.go.tz, Toll free: 08001100834

1. Introduction

GABALIN 300 is a generic medicine of Gabapentin 300 mg capsules. GABALIN 300 is an antileptic medicine belonging to N02BF01 - Other antiepileptics group. GABALIN 300 exerts is activity by binding to the α2δ (alpha-2-delta) subunit of voltage-gated calcium channels . GABALIN 300 is approved in Tanzania for use in adults and children aged 6 years and above .

1.1 Product details

Registration number	TAN 20 HM 0334
Brand name	GABALIN 300
Generic name, strength and form	Gabapentin 300 mg capsules
ATC classification	N02BF01
Distribution category	POM
Country of origin	India
Associated product	NA
Marketing Authorization Holder	Lincoln Pharmaceutical Trimul Estate, Khatraj, Taluka , Kalol Gandhinaga, Gujarat
Local Technical Representative	HEKO PHARMACY LTD. P O Box 2657, Plot No.32/57,Sikukuu/Tandamti Street, Kariakoo, DAR ES SALAAM

1.2 Assessment procedure

The application for registration of GABALIN 300 was submitted on 30/04/2019. The product underwent full assessment. Assessment was completed in 2 rounds of evaluation. GABALIN 300 was registered on 25/09/2020.

1.3 Information for users

Visual description of the finished product	Pink / white coloured, capsule size “0” hard gelatin capsule, containing white colour granular powder
Primary packing material	Alu-PVDC Blister Pack
Secondary packing materials	Carton
Shelf-life and storage condition	36 months Store below 30^0C
Route of administration	Oral
Therapeutic indications	Gabapentin Capsule is indicated for treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults, as adjunctive therapy in treatment of

	partial onset seizures, with and without secondary generalization, in adults and pediatrics patients 6 years and older with epilepsy and as monotherapy in treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above.

2. Labelling and product information

Summary of product characteristics

The SmPC included all the relevant information to ensure correct and safe use of the medicine by healthcare providers. The complete SmPC can be accessed here.

Package insert/leaflet

The package insert is confirmed to be derived from the SmPC and contains sufficient data for the end user. Since the product is POM that is intended for long term use, the package insert contains full prescribing information as per SmPC and simplified information for patients.

Container labels

The product label information is presented in English. Details in the secondary pack label include:
Brand name: GABALIN 300
Composition: Gabapentin 300 mg capsules
Pack size: 10 capsules
Manufacturing details: batch number, manufacturing date, expiry date
Storage conditions: below 30^0C
Manufacturer address: Lincoln Pharmaceuticals Ltd , Trimul Estate, Khatraj, Taluka , Kalol
Unique identifier: NA
Special warnings/precautions or instructions for use: The product contains lactose

The details of the primary pack include:
Brand name and strength: GABALIN 300
Manufacturing details:
Name of manufacturer: Lincoln Pharmaceuticals Ltd

The content of the primary and secondary labels was aligned to the requirements of the Part V of the Compendium: Guidelines on Format and Content of Product Labels for Medicinal products. The label contains sufficient information for proper identification of the medicine and post marketing follow up of the product.
Describe any approved deviation to the requirements and the justification for the deviation.

3. Scientific discussion

Quality of Active Pharmaceutical Ingredient(s)

Information on quality of the API was submitted in form of Full details.

General properties
Gabapentin API is compendia in USP.
Molecular formula: $C_9H_{17}NO_2$
Chemical name:
(i) 1-(Aminomethyl) cyclohexane acetic acid
(ii) Cyclohexaneacetic acid, 1-(aminomethyl)
Structure:



Critical physico-chemical properties of the API were freely soluble in water and sparingly soluble in methanol, it exhibitis polymorphism where form II is consistently manufactured.

Manufacture
The API manufacturing site, Strides Shasun Limited, A-1/B, Sipcot Industrial Complex, Kudikadu Village Cuddalore – 607 005, India was noted to comply with WHO GMP requirements as evidenced by the GMP certificate issued by Tamil Nadu Food Safety and Drug Control Administration. Gabapentin API is manufactured by chemical synthesis using conventional techniques. Sufficient controls of quality of materials and in-process checks were employed throughout the manufacturing process.

Specifications
The API specifications were set as per USP standards and ICHQ3A. The parameters monitored during quality control are: description, solubility, identification, pH, water content, residue on ignition,heavy metals, assay, related compounds,residual solvents, chlorides and foreign matters. Compliance to these specifications were established via batch analysis data and stability studies.

Stability and container closure system

The re-test period of Gabapentin API is 48 months when packed in colourless translucent LDPE bags and stored at below 25°C.

Quality of the Finished Pharmaceutical Product

Formulation

GABALIN 300 is a Pink / white coloured, capsule size “0” hard gelatin capsule, containing white colour granular powder. GABALIN 300 contains Gabapentin and other ingredients listed hereafter pregelatinized starch (starch 1500), maize starch, purified talc and magnesium stearate.The quantities of all ingredients are confirmed to be in line with the recommendations of Handbook of Pharmaceutical Excipients, Edition 8th in terms of function and quantities. Ingredient, <excipient> is of safety concern therefore appropriate warnings were included in the product label.

Manufacture

The finished product was manufactured at Lincoln Pharmaceuticals Limited, Trimul Estate, Khatraj, Tal. Kalol, Dist. Gandhinagar, Gujarat, India.The compliance of the site to TMDA GMP standards was confirmed through site inspection on 19 June 2019.

Specifications

The FPP is compendia in USP. The manufacturer controls the quality of the finished product as per USP, in-house and ICHQ3B requirements. The parameters monitored during quality control are: description, identification, average net content, uniformity of dosage units,disintegration test, locking length , dissolution, organic impurities, assay, microbial limit test.Compliance to the standard was established using batch analysis data and stability data.

Stability and container closure system

Stability studies were conducted on 3 batches of the finished product stored at 30° ± 2°C/75 % ± 5% RH for 36 months and 40° ± 2°C/75% ± 5% RH for 6 months. Based on the stability data presented, the approved shelf-life is 36 months when stored in Alu/PVDC blister Pack at below 30°.

Safety and efficacy information

Safety and efficacy of GABALIN 300 was established through bioequivalence trial. BE trial report number GAB_244_17 was submitted.

Study title	A Randomized, open label, Balanced, two treatment, two period, two sequence, single dose, crossover bioequivalence study of Gabapentin Capsule USP 300 mg of Lincoln

	Pharmaceuticals Ltd., India with Neurontin ® (Gabapentin 300 mg) of Pfizer Ltd. UK in 24 normal, healthy, adult, human subjects under fasting condition	
Study design	Open label, randomised, two-period, two-treatment, two-sequence single dose cross over comparative bioequivalence study on 24 health adult human subjects under fasting condition with wash out period of 7 days between two periods	
Study site	Om Sai Clinical Research Pvt. Ltd. C.S.T. No. 379/1-6, Karnal Chowki, Peth Bhag, Sangli – 416416, Maharashtra, India	
Study dates	06-March-2017 to 25- March-2017 (clinical and bioanalytical)	
Primary objective	To assess the bioequivalence of Gabapentin Capsule USP 300 mg of Lincoln Pharmaceuticals Ltd., India with NeurontinR (Gabapentin 300 mg) of Pfizer Ltd. UK in 24 normal, healthy, adult, human subjects under fasting condition	
Secondary objective	To assess the safety and tolerability of the test formulation in healthy, adult, male, human Subjects based on the observed incidence, severity, and type of adverse events and/or adverse drug reactions, if any	
Number of participants	24	
Monitored parameters	Cmax, AUCt, AUCinf	
Investigational medicinal products	Test Product Gabapentin Capsule of Lincoln Pharmaceuticals Ltd., India	Reference product Neurontin® of Pfizer Ltd. UK
	Strength: 300 mg Batch number: EC-7101 Expiry date: 12/2019	Strength: 300 mg Batch number: R22310 Expiry date: 11/2018
Analytical method	LC-MS/MS	
Statistical method		

Efficacy results are summarized as follows:

Parameter	Test	Reference	% Ratio of geometric means	90 % Confidence interval	DF	CV (%)

AUC0-t (ng*hr/ml)	18697.98 ± 4025.05	18319.79 ± 3413.55	102.06	83.99-110.9		13.50
AUC0-inf (ng*hr/ml)	19838.45 ± 4362.57	19452.58 ± 3828.15	101.98	84.13 – 110.4		14.16
Cmax (ng/ml)	2599.74 ± 481.69	2294.69± 485.34	113.29	90.64 – 120.85		13.79

The acceptance limits of 80 – 125% are met by the AUC and Cmax values. Furthermore, the safety profile of the test product is similar to that of reference product. Therefore, GABALIN 300 is equivalent and interchangeable with Neurontin ®under acceptable in vivo experimental conditions.

4. Benefit-Risk Assessment and Conclusion

On basis ofthe data submitted, the current state of knowledge and compliance to Good Manufacturing Practice, the benefit of the product outweighs the risks associated with its use when used in accordance to the summary of product characteristics. GABALIN 300 is recommended for registration.

5. Post-approval updates

Variation applications

Reference number	Date submitted	Change requested	Recommendation	Granting date

Feedback from pharmacovigilance, post marketing surveillance and enforcement activities

Type of feedback	Impact	Response

Re-registration applications

Application for renewal of registration was submitted on <DDMMYYYY>. The application was finalized in <number> rounds of evaluation. The product was confirmed to still be compliant to the standards of quality, safety and efficacy, hence registration was renewed on <DDMMYYYY>.

PART 5: CHANGE HISTORY

Version number	Date	Description of update	Section(s) Modified	Approval date

Annex I: Mock up label



Effective date: 03/10/2022